Welcome to our dedicated page for Purple Biotech SEC filings (Ticker: PPBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Purple Biotech Ltd. SEC filings document foreign private issuer current reports for a clinical-stage oncology biotechnology company and its PPBT American depositary shares. Recent Form 6-K filings attach press releases and corporate presentations covering CAPTN-3, IM1240 and IM1305, preclinical and toxicology data, oncology development plans, collaboration announcements, scientific advisory activity, operating results, and risk-related forward-looking disclosures.
The filing record also reflects capital-structure and market-status matters, including ADS ratio disclosures and Nasdaq minimum bid price compliance. The company’s 6-K reports are incorporated by reference into registration statements on Form F-3 and Form S-8, linking current reports to shelf registration and equity-plan disclosure frameworks.
PURPLE BIOTECH LTD. executive Michael Schickler filed an initial ownership report showing 9,254,472 Ordinary Shares, including 6,958,334 unvested restricted stock units that vest over time and settle in Ordinary Shares. He also holds several stock options over Ordinary Shares with exercise prices between $0.10828125 and $0.00309375 per share, expiring between April 2027 and October 2030, some already vested and others vesting in quarterly installments.
PURPLE BIOTECH LTD. director Shai S. Lankry filed an initial ownership report showing a sizable equity position. He holds 3,550,000 Ordinary Shares, including 3,254,167 unvested restricted stock units that settle in shares or ADSs. He also holds stock options to purchase 3,000,000 Ordinary Shares at an exercise price of $0.01359375 per share and options to purchase 3,550,000 Ordinary Shares at $0.00309375 per share, both vesting over several years and expiring in 2030.
Purple Biotech Ltd. filed a Form 6-K to furnish a press release announcing an AI-driven collaboration with Converge Bio to advance its next-generation tri-specific antibody platform. The partnership uses Converge Bio’s generative AI to design and optimize oncology-focused antibodies, aiming to speed discovery and improve molecule quality.
Purple Biotech plans to apply these AI insights to its CAPTN-3 platform of masked tri-specific antibodies that engage both T cells and NK cells, with lead candidates IM1240 and IM1305 in preclinical development. The company also highlights additional clinical-stage assets CM24 and NT219, whose further progress depends on partnering or investment.
Purple Biotech Ltd. provides an updated corporate presentation describing its immuno-oncology pipeline and financial position. The company highlights its CAPTN-3 tri-specific antibody platform, led by IM1240 for solid tumors, with GLP toxicology planned in Q3 2026, an IND submission in Q4 2026 and first-in-human Phase 1 initiation in Q1 2027.
Two additional clinical-stage assets, CM24 for pancreatic cancer and NT219 for recurrent/metastatic head and neck cancer, have Phase 2 data and are positioned for partnerships. The company reports cash of $9.5 million and a cash runway extending into the first half of 2027, with 930K shares outstanding as of December 31, 2025.
Purple Biotech Ltd., an Israel-based clinical-stage biotechnology company, files its Form 20-F annual report for the year ended December 31, 2025. The company reports cumulative losses of approximately $171 million since starting its pharmaceutical R&D activities and remains unprofitable.
Purple Biotech is developing a preclinical tri-specific antibodies platform, CAPTN-3, with lead candidates IM1240 and IM1305, plus two oncology candidates in clinical trials, CM24 and NT219. As of December 31, 2025, it had 1,858,911,801 ordinary shares outstanding and maintains American Depositary Shares listed on the NASDAQ Capital Market.
The report emphasizes significant risks: dependence on a limited pipeline, the need to raise substantial additional capital, reliance on third parties for manufacturing and clinical work, extensive regulatory uncertainty, and the possibility of NASDAQ delisting if listing requirements are not met.
PURPLE BIOTECH LTD. director Robert E. Gagnon filed a Form 3 disclosing his equity stake in the company. He reports 3,062,500 Ordinary Shares held directly, including 2,454,167 unvested restricted stock units that vest over time and settle in Ordinary Shares.
Gagnon also holds three stock option awards: options for 112,500 Ordinary Shares at an exercise price of $0.146765625 per share expiring on December 29, 2026; options for 300,000 Ordinary Shares at $0.059375 per share expiring on April 24, 2028; and options for 2,650,000 Ordinary Shares at $0.00309375 per share expiring on October 21, 2030. The filing states that the Ordinary Shares may be represented by American Depositary Shares, with each ADS currently equal to 2,000 Ordinary Shares. No purchases or sales are reported; this is an initial ownership disclosure.
Purple Biotech Ltd. reports that it has regained compliance with the Nasdaq Capital Market’s minimum bid price requirement. Nasdaq’s Listing Qualifications Department confirmed that the company now meets Nasdaq Listing Rule 5550(a)(2) for continued listing.
To regain compliance, Purple Biotech’s American Depositary Shares maintained a minimum closing bid price of at least $1.00 per share for 10 consecutive business days, a condition achieved on March 13, 2026. The company continues to develop its next-generation immunotherapy platform, including lead candidates IM1240 and IM1305 and other oncology assets.
Purple Biotech Ltd. reported a much wider full-year 2025 net loss of $26.4 million, driven mainly by a $20.5 million non-cash impairment of its CM24 and NT219 programs as it shifts focus to its CAPTN-3 tri-specific antibody platform.
Adjusted operating loss improved to $6.7 million from $10.4 million in 2024, reflecting lower clinical trial spending, while research and development expenses fell to $3.7 million from $7.6 million. Cash, cash equivalents and deposits totaled about $9.5 million as of December 31, 2025, which the company expects to fund operations into 2027.
The lead CAPTN-3 candidate IM1240 achieved toxicology and manufacturing milestones, and IM1305 was named a development candidate. Separately, CEO Gil Efron will step down in August 2026 for health reasons, remaining on the board and leading corporate development while a search for a new CEO is underway.
Purple Biotech Ltd. reported a much wider full-year 2025 net loss of $26.4 million, driven mainly by a $20.5 million non-cash impairment of its CM24 and NT219 programs as it shifts focus to its CAPTN-3 tri-specific antibody platform.
Adjusted operating loss improved to $6.7 million from $10.4 million in 2024, reflecting lower clinical trial spending, while research and development expenses fell to $3.7 million from $7.6 million. Cash, cash equivalents and deposits totaled about $9.5 million as of December 31, 2025, which the company expects to fund operations into 2027.
The lead CAPTN-3 candidate IM1240 achieved toxicology and manufacturing milestones, and IM1305 was named a development candidate. Separately, CEO Gil Efron will step down in August 2026 for health reasons, remaining on the board and leading corporate development while a search for a new CEO is underway.
Purple Biotech Ltd. is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS for 200 ordinary shares to one ADS for 2,000 ordinary shares. Trading reflecting the new ratio is expected to begin on or about March 2, 2026.
For ADS holders, this acts as a one-for-ten reverse ADS split: every 10 existing ADSs will be exchanged for 1 new ADS, with no action needed for uncertificated holders. Fractional ADSs will be sold by the depositary, and net cash from those fractions will be distributed to holders.
The move is primarily intended to help the company regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The ADSs will keep the “PPBT” symbol and receive a new CUSIP. The ratio change does not affect the company’s ordinary shares on the Tel Aviv Stock Exchange.
Susquehanna Securities, LLC filed a Schedule 13G reporting beneficial ownership of 93,953,400 Ordinary Shares of Purple Biotech Ltd., equal to 5.2% of the class. The position is held through 469,767 ADSs, with each ADS representing 200 Ordinary Shares.
Based on the company’s disclosure that 1,806,089,801 Ordinary Shares were outstanding as of October 20, 2025, Susquehanna’s holdings represent a significant but minority passive stake. The filing states the securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Purple Biotech.